Current TopicsFrom centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades*,**
Section snippets
Centrocytic lymphoma
CCL was described by Lennert et al as “diffuse germinocytoma” in a symposium on non-Hodgkin lymphoma in London, England, in 1973 (Lennert, personal communication). In the 1975 publication of this work, diffuse germinocytoma was described as a tumor that “looks very much like CLL” but lacks proliferation centers.1 It is composed of lymphocytes slightly larger than CLL cells with nuclei that are “very irregular in shape (not round) and often cleaved” with “very fine” chromatin and very small to
Mantle cell lymphoma
In 1992, the International Lymphoma Study Group proposed that the term mantle cell lymphoma replace CCL as well as other terms that were being used for this and other closely related entities.17 Banks et al noted that “the data indicate that the small cleaved cells of centrocytic lymphoma [lymphocytic lymphoma of intermediate differentiation/intermediate lymphocytic lymphoma, and mantle zone lymphoma] may be the neoplastic counterpart of cells normally residing in the follicle mantle. We
Identification of cyclin D1
The t(11;14)(q13;q32) was first identified in the 1970s as an apparently rare cytogenetic event in B-cell non-Hodgkin lymphoma and lymphocytic leukemia, and the translocation breakpoint was first cloned in 1984 by Tsujimoto et al.27 As in most B-cell neoplasms, the break involved the immunoglobulin heavy chain gene locus, as well as a site at 11q13 designated bcl-1 (B-cell leukemia/lymphoma 1) for the oncogene postulated to exist at that locus. The gene remained elusive until its identification
Cell cycle–regulatory pathways and the development of MCL
Cell cycle regulation is central to the control of cellular proliferation and differentiation programs. One of the primary regulatory checkpoints occurs at the “restriction point” in late G1 phase, where active cyclin/cyclin-dependent kinase (CDK) complexes form that are essential for progression into S phase (Fig 7).
Clinical approaches
MCL has one of the poorest overall prognoses of the non-Hodgkin lymphomas.127 However, there may be considerable heterogeneity in both therapeutic response and overall survival as described above. Response to any standard chemotherapy regimen is generally short-lived, and consolidation therapy with autologous stem cell transplantation has had little success.128 However, recent reports of the induction chemotherapy regimen HyperCVAD followed by autologous or allogeneic stem cell transplantation
Acknowledgements
The technical assistance of Margaret Whitefield and Patricia Ennis is gratefully acknowledged. The authors thank Benjamin Williams for assistance with manuscript preparation.
References (134)
- et al.
Histopathology of malignant lymphomas
Clin Haematol
(1974) - et al.
Lymphocytic lymphoma of intermediate differentiation-mantle zone lymphoma: A distinct subtype of B-cell lymphoma
Hum Pathol
(1987) - et al.
European Lymphoma Task Force (ELTF)
Report of the workshop on Mantle Cell Lymphoma (MCL)
Ann Oncol
(1994) - et al.
Mantle cell lymphoma: A clinicopathologic study of 80 cases
Blood
(1997) - et al.
Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period
Ann Oncol
(1995) - et al.
A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study
Blood
(1995) - et al.
Homing receptor alpha4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma
Am J Pathol
(1998) - et al.
Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast
Cell
(1991) - et al.
Human D-type cyclin
Cell
(1991) - et al.
Genotypic characterization of centrocytic lymphoma: Frequent rearrangement of the chromosome 11 bcl-1 locus
Blood
(1990)
Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation
Blood
Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: Analysis with multiple breakpoint probes
Blood
Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas
Blood
Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene
Hum Pathol
In situ hybridization detection of cyclin D1 mRNA in centrocytic/mantle cell lymphoma
Ann Oncol
Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: A clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
Blood
Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization
Blood
Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization
Blood
Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization
Am J Pathol
Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant
Cancer Genet Cytogenet
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma
Blood
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
Blood
Multiple myeloma: Increasing evidence for a multistep transformation process
Blood
Blastic mantle cell leukemia: An unusual presentation of blastic mantle cell lymphoma
Mod Pathol
Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age
Cell
Role of the cyclin-dependent kinase inhibitors in the development of cancer
Blood
Regulated genomic instability and neoplasia in the lymphoid lineage
Blood
G1 phase progression: Cycling on cue
Cell
Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma
Blood
Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
Blood
p53 in hematologic malignancies
Blood
p53 mutation is associated with progression in follicular lymphomas
Blood
Absence of WAF1 mutations in a variety of human malignancies
Blood
Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia
Blood
p16INK4A and p15INK4B gene deletions in primary leukemias
Blood
Deletions and rearrangement of CDKN2 in lymphoid malignancy
Blood
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma
Blood
Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas
Blood
Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients
Blood
Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas
Blood
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies
Blood
Cytological and functional criteria for the classification of malignant lymphomata
Br J Cancer
Mantle-cell lymphoma
Semin Hematol
Centrocytic lymphoma: A distinct clinicopathologic, immunophenotypic, and genotypic entity
Pathol Annu
Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations
Am J Surg Pathol
Malignant lymphoma, intermediate lymphocytic type: A clinicopathologic study of 42 cases
Cancer
Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma
Cancer
Classification of non-Hodgkin's lymphomas
Lancet
Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes)
Br J Cancer
Histopathology of Non-Hodgkin's Lymphomas (Based on the Kiel Classification)
Cited by (0)
- *
Based in part on a lecture (by S.H.S.) at Jefferson Medical College, Philadelphia, PA, February 24, 1999.
- **
Address correspondence and reprint requests to Steven H. Swerdlow, MD, Division of Hematopathology, UPMC-Presbyterian, Room PUH C606, 200 Lothrop St, Pittsburgh, PA 15213.